ZA200409096B - Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins - Google Patents
Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins Download PDFInfo
- Publication number
- ZA200409096B ZA200409096B ZA200409096A ZA200409096A ZA200409096B ZA 200409096 B ZA200409096 B ZA 200409096B ZA 200409096 A ZA200409096 A ZA 200409096A ZA 200409096 A ZA200409096 A ZA 200409096A ZA 200409096 B ZA200409096 B ZA 200409096B
- Authority
- ZA
- South Africa
- Prior art keywords
- hyaluronic acid
- osteogenic
- composition
- bmp
- bone
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims description 85
- 108090000623 proteins and genes Proteins 0.000 title claims description 79
- 102000004169 proteins and genes Human genes 0.000 title claims description 77
- 230000002188 osteogenic effect Effects 0.000 title claims description 74
- 229960003160 hyaluronic acid Drugs 0.000 title claims description 69
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims description 62
- 239000007787 solid Substances 0.000 title claims description 34
- 238000012384 transportation and delivery Methods 0.000 title claims description 7
- 239000000969 carrier Substances 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims description 143
- 210000000988 bone and bone Anatomy 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 45
- 239000000463 material Substances 0.000 claims description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 29
- -1 hyaluronic acid ester Chemical class 0.000 claims description 25
- 229940122361 Bisphosphonate Drugs 0.000 claims description 23
- 150000004663 bisphosphonates Chemical group 0.000 claims description 23
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 150000002148 esters Chemical class 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 15
- 229940099552 hyaluronan Drugs 0.000 claims description 15
- 229920005615 natural polymer Polymers 0.000 claims description 15
- 229920001059 synthetic polymer Polymers 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 230000001009 osteoporotic effect Effects 0.000 claims description 14
- 230000007547 defect Effects 0.000 claims description 13
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 10
- 238000000465 moulding Methods 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000003405 delayed action preparation Substances 0.000 claims description 6
- 230000032050 esterification Effects 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 5
- 229940062527 alendronate Drugs 0.000 claims description 5
- 239000012062 aqueous buffer Substances 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 4
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 4
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 4
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 4
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 4
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 claims description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 4
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 4
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 4
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 4
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims description 4
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 claims description 4
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 4
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 4
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 4
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002286 clodronic acid Drugs 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 229940015872 ibandronate Drugs 0.000 claims description 4
- 229950006971 incadronic acid Drugs 0.000 claims description 4
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims description 4
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 4
- 229950010733 neridronic acid Drugs 0.000 claims description 4
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 4
- 229940046231 pamidronate Drugs 0.000 claims description 4
- 229940089617 risedronate Drugs 0.000 claims description 4
- 229940019375 tiludronate Drugs 0.000 claims description 4
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 3
- IWLDTXOHXPDPQG-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-3-pyrrolidin-1-ylpropyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)(O)C(P([O-])([O-])=O)(O)CCN1CCCC1 IWLDTXOHXPDPQG-UHFFFAOYSA-L 0.000 claims description 3
- 229940009626 etidronate Drugs 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 6
- 230000007928 solubilization Effects 0.000 claims 2
- 238000005063 solubilization Methods 0.000 claims 2
- 101150072730 Bmp6 gene Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 53
- 108010023714 recombinant human bone morphogenetic protein-2 Proteins 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 20
- 208000001132 Osteoporosis Diseases 0.000 description 19
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 18
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 18
- 230000011164 ossification Effects 0.000 description 18
- 229940112869 bone morphogenetic protein Drugs 0.000 description 17
- 238000009472 formulation Methods 0.000 description 17
- 230000002138 osteoinductive effect Effects 0.000 description 17
- 206010017076 Fracture Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000013543 active substance Substances 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 208000010392 Bone Fractures Diseases 0.000 description 8
- 206010020100 Hip fracture Diseases 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940049906 glutamate Drugs 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000000337 buffer salt Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 150000004804 polysaccharides Chemical class 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 206010065687 Bone loss Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 102000016970 Follistatin Human genes 0.000 description 3
- 108010014612 Follistatin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 102000006533 chordin Human genes 0.000 description 3
- 108010008846 chordin Proteins 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000017234 Bone cyst Diseases 0.000 description 2
- 206010061728 Bone lesion Diseases 0.000 description 2
- 241000202252 Cerberus Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 208000003044 Closed Fractures Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 241000027355 Ferocactus setispinus Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 102000002746 Inhibins Human genes 0.000 description 2
- 108010004250 Inhibins Proteins 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 210000001520 comb Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 210000001981 hip bone Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920003175 pectinic acid Polymers 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000007409 radiographic assessment Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 229920000260 silastic Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025745 Cerberus Human genes 0.000 description 1
- 101710010675 Cerberus Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 241000722985 Fidia Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000027587 GPCRs class F Human genes 0.000 description 1
- 108091008884 GPCRs class F Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101100175313 Mus musculus Gdf3 gene Proteins 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000897276 Termes Species 0.000 description 1
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- QGKAVFXNTADNHB-UHFFFAOYSA-N [Mg].[K].[Ca] Chemical compound [Mg].[K].[Ca] QGKAVFXNTADNHB-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 210000001909 alveolar process Anatomy 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000004664 etidronic acid derivatives Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001248 thermal gelation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38159002P | 2002-05-17 | 2002-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200409096B true ZA200409096B (en) | 2006-06-28 |
Family
ID=29584319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200409096A ZA200409096B (en) | 2002-05-17 | 2004-11-10 | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050287135A1 (ru) |
| EP (1) | EP1519744A4 (ru) |
| JP (1) | JP4879482B2 (ru) |
| CN (1) | CN1665525A (ru) |
| AR (1) | AR039548A1 (ru) |
| AU (1) | AU2003228958C1 (ru) |
| BR (1) | BR0310087A (ru) |
| CA (1) | CA2486113A1 (ru) |
| CO (1) | CO5631458A2 (ru) |
| EA (1) | EA008354B1 (ru) |
| IL (1) | IL165077A0 (ru) |
| MX (1) | MXPA04011337A (ru) |
| NO (1) | NO20045507L (ru) |
| NZ (1) | NZ536478A (ru) |
| TW (2) | TW200638946A (ru) |
| WO (1) | WO2003099992A2 (ru) |
| ZA (1) | ZA200409096B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0608053B1 (en) * | 1993-01-11 | 1999-12-01 | Canon Kabushiki Kaisha | Colour display system |
| ES2225241T3 (es) * | 1999-10-15 | 2005-03-16 | Genetics Institute, Llc | Formulaciones de acido hialuronico para suministrar proteinas osteogenicas. |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| ES2282904T3 (es) | 2003-09-12 | 2007-10-16 | Wyeth | Barras solidas de fosfato calcico inyectables para el suministro de proteinas osteogenicas. |
| CZ13928U1 (cs) * | 2003-10-08 | 2004-01-20 | Cpn Spol. S R.O. | Dietetický přípravek pro prevenci a léčbu osteoporózy |
| AR046773A1 (es) * | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| CA2576659A1 (en) * | 2004-08-23 | 2006-03-02 | Teva Pharmaceutical Industries Ltd. | Solid and crystalline ibandronate sodium and processes for preparation thereof |
| ITMI20052515A1 (it) * | 2005-12-29 | 2007-06-30 | Abiogen Pharma Spa | Formulazione farmaceutica per il trattamento della osteoartrite |
| AU2006343862A1 (en) * | 2006-05-23 | 2007-11-29 | Mathys Ag Bettlach | Solid precursor for the preparation of a pasty bone replacement material by admixture of a liquid. |
| WO2008040763A1 (en) * | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
| FR2919188B1 (fr) * | 2007-07-27 | 2010-02-26 | Proteins & Peptides Man | Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps |
| WO2009127940A1 (fr) * | 2008-04-14 | 2009-10-22 | Adocia | Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique |
| WO2009127939A1 (fr) * | 2008-04-14 | 2009-10-22 | Adocia | Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un support organique |
| US8759322B2 (en) | 2008-11-05 | 2014-06-24 | National University Corporation Tokyo Medical And Dental University | Hyaluronic acid derivative and pharmaceutical composition thereof |
| HUE055260T2 (hu) | 2009-07-10 | 2021-11-29 | Implantica Patent Ltd | Csípõízületi eszköz |
| US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
| US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| KR102016745B1 (ko) * | 2013-02-01 | 2019-09-02 | 아이진 주식회사 | Ｂｍｐ―７ 및 부형제를 포함하는 흉터 형성의 감소 또는 억제용 조성물 |
| US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
| US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| CN118045230A (zh) * | 2018-09-14 | 2024-05-17 | 奥索赛尔有限公司 | 人造骨膜 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2465257A (en) * | 1945-09-12 | 1949-03-22 | Universal Moulded Products Cor | Laminated tubular article |
| CH563767A5 (ru) * | 1973-01-30 | 1975-07-15 | Pheulpin Jean | |
| DE2657370C2 (de) * | 1976-12-17 | 1982-11-11 | Hans Dr.med. Dr.med.dent. 8000 München Scheicher | Mittel zum Bedecken und/oder Ausfüllen von Knochendefekten |
| DE2732848A1 (de) * | 1977-07-18 | 1979-02-08 | Schering Ag | Diurethane, herbizide mittel enthaltend diese verbindungen sowie verfahren zu ihrer herstellung |
| US4455256A (en) * | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| US4727028A (en) * | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
| US4394370A (en) * | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| IL68218A (en) * | 1983-03-23 | 1985-12-31 | Univ Ramot | Compositions for cartilage repair comprising embryonal chondrocytes |
| US4434094A (en) * | 1983-04-12 | 1984-02-28 | Collagen Corporation | Partially purified osteogenic factor and process for preparing same from demineralized bone |
| US4795804A (en) * | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
| US4923805A (en) * | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| GB8334498D0 (en) * | 1983-12-24 | 1984-02-01 | Beecham Group Plc | Compounds |
| US4804744A (en) * | 1984-01-04 | 1989-02-14 | International Genetic Engineering, Inc. | Osteogenic factors |
| US4662884A (en) * | 1984-04-25 | 1987-05-05 | University Of Utah Research Foundation | Prostheses and methods for promoting nerve regeneration |
| US4596574A (en) * | 1984-05-14 | 1986-06-24 | The Regents Of The University Of California | Biodegradable porous ceramic delivery system for bone morphogenetic protein |
| CA1341617C (en) * | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibin isolated from ovarian follicular fluid |
| US4843063A (en) * | 1984-07-16 | 1989-06-27 | Collagen Corporation | Polypeptide cartilage-inducing factors found in bone |
| EP0169016B2 (en) * | 1984-07-16 | 2004-04-28 | Celtrix Pharmaceuticals, Inc. | Polypeptide cartilage-inducing factors found in bone |
| US5187263A (en) * | 1984-10-12 | 1993-02-16 | Zymogenetics, Inc. | Expression of biologically active PDGE analogs in eucaryotic cells |
| US4563350A (en) * | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
| HU201775B (en) * | 1984-12-27 | 1990-12-28 | Suntory Ltd | Process for purifying interferon |
| US4681763A (en) * | 1985-06-11 | 1987-07-21 | University Of Medicine And Dentistry Of New Jersey | Composition for stimulating bone growth |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US5089396A (en) * | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| US4798885A (en) * | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
| US5215893A (en) * | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| US5133755A (en) * | 1986-01-28 | 1992-07-28 | Thm Biomedical, Inc. | Method and apparatus for diodegradable, osteogenic, bone graft substitute device |
| US4737578A (en) * | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
| US4758233A (en) * | 1986-04-22 | 1988-07-19 | N.J. Phillips TPY. Limited | Cream applicator |
| NL8601328A (nl) * | 1986-05-23 | 1987-12-16 | Langen Research | Inrichting voor het met een massa, in het bijzonder pasteuze massa, injekteren van vlees. |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5108922A (en) * | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
| US5631142A (en) * | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
| US5543394A (en) * | 1986-07-01 | 1996-08-06 | Genetics Institute, Inc. | Bone morphogenetic protein 5(BMP-5) compositions |
| US6150328A (en) * | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US6432919B1 (en) * | 1986-07-01 | 2002-08-13 | Genetics Institute, Inc. | Bone morphogenetic protein-3 and compositions |
| US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5187076A (en) * | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| US5459047A (en) * | 1986-07-01 | 1995-10-17 | Genetics Institute, Inc. | BMP-6 proteins |
| US5019087A (en) * | 1986-10-06 | 1991-05-28 | American Biomaterials Corporation | Nerve regeneration conduit |
| IT1198449B (it) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| US5124316A (en) * | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
| US5202120A (en) * | 1987-09-11 | 1993-04-13 | Case Western Reserve University | Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
| US5108753A (en) * | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
| US5011691A (en) * | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5258494A (en) * | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
| US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5284756A (en) * | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
| US5106626A (en) * | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
| US5011486A (en) * | 1988-11-18 | 1991-04-30 | Brown University Research Foundation | Composite nerve guidance channels |
| US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US4920962A (en) * | 1988-11-23 | 1990-05-01 | Claude Proulx | Splint-like element for use in end-to-end nerve suture |
| US5217867A (en) * | 1988-11-30 | 1993-06-08 | The Salk Institute For Biological Studies | Receptors: their identification, characterization, preparation and use |
| US5202421A (en) * | 1988-12-27 | 1993-04-13 | Mochida Pharmaceutical Co., Ltd. | Anticoagulant substance obtained from urine and process for the preparation thereof |
| US5026381A (en) * | 1989-04-20 | 1991-06-25 | Colla-Tec, Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| WO1991000103A1 (en) * | 1989-06-29 | 1991-01-10 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1 |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5422340A (en) * | 1989-09-01 | 1995-06-06 | Ammann; Arthur J. | TGF-βformulation for inducing bone growth |
| US5236456A (en) * | 1989-11-09 | 1993-08-17 | Osteotech, Inc. | Osteogenic composition and implant containing same |
| US5290271A (en) * | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
| WO1991017777A2 (en) | 1990-05-22 | 1991-11-28 | University Of Florida | Injectable bioactive glass compositions and methods for tissue reconstruction |
| US5218090A (en) * | 1990-06-12 | 1993-06-08 | Warner-Lambert Company | EGF receptor truncates |
| US5206028A (en) * | 1991-02-11 | 1993-04-27 | Li Shu Tung | Dense collagen membrane matrices for medical uses |
| US5208219A (en) * | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
| US5318898A (en) * | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| IT1247472B (it) * | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
| US5216126A (en) * | 1991-06-19 | 1993-06-01 | Genentech, Inc. | Receptor polypeptides and their production and uses |
| US6287816B1 (en) * | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
| US5306307A (en) * | 1991-07-22 | 1994-04-26 | Calcitek, Inc. | Spinal disk implant |
| WO1993009229A1 (en) * | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| SE469653B (sv) | 1992-01-13 | 1993-08-16 | Lucocer Ab | Poroest implantat |
| AU666712B2 (en) | 1992-02-28 | 1996-02-22 | Cohesion Technologies, Inc. | Injectable ceramic compositions and methods for their preparation and use |
| IT1259090B (it) | 1992-04-17 | 1996-03-11 | Fidia Spa | Biomaterialli per protesi d'osso |
| IT1259100B (it) | 1992-05-20 | 1996-03-11 | Lanfranco Callegaro | Uso di idrogeli per il bloccaggio di sistemi protesici |
| SK329592A3 (en) | 1992-11-03 | 1995-03-08 | Stu Chemickotechnologicka | Method of preparation of bioactive material |
| US6221958B1 (en) * | 1993-01-06 | 2001-04-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5420243A (en) * | 1993-01-26 | 1995-05-30 | Celtrix Pharmaceuticals, Inc. | Biologically active TGF-β2 peptides |
| GB9308060D0 (en) * | 1993-04-19 | 1993-06-02 | Cancer Res Campaign Tech | Stem cell inhibitor |
| EP1378572B1 (en) * | 1993-05-12 | 2006-10-25 | Genetics Institute, LLC | Bmp-11 compositions |
| US5637480A (en) * | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| DE69434739T2 (de) * | 1993-08-26 | 2007-05-10 | Genetics Institute, LLC, Cambridge | Menschliche Knochen-morphogenetische Proteine zur Verwendung bei neuronaler Rehgeneration |
| ATE319823T1 (de) * | 1993-12-07 | 2006-03-15 | Inst Genetics Llc | Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen |
| US6027919A (en) * | 1993-12-07 | 2000-02-22 | Genetics Institute, Inc. | BMP-12 and BMP-13 proteins and DNA encoding them |
| US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| US5520923A (en) * | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| EP1364656B1 (en) * | 1995-06-05 | 2013-11-20 | Genetics Institute, LLC | Use of bone morphogenetic proteins for healing and repair of connective tissue attachment |
| US5716413A (en) * | 1995-10-11 | 1998-02-10 | Osteobiologics, Inc. | Moldable, hand-shapable biodegradable implant material |
| US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| IT1282219B1 (it) * | 1995-12-20 | 1998-03-16 | Fidia Advanced Biopolymers Srl | Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa |
| CN1149088C (zh) | 1996-03-05 | 2004-05-12 | 奥奎斯特公司 | 骨生长促进组合物及其用途 |
| NZ331238A (en) | 1996-03-05 | 2000-05-26 | Orquest Inc | Method of promoting bone growth with hyaluronic acid and growth factors (bFGF) |
| WO1997045532A1 (en) | 1996-05-28 | 1997-12-04 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
| IT1288290B1 (it) | 1996-06-21 | 1998-09-11 | Fidia Spa In Amministrazione S | Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie |
| EP1350525A3 (en) | 1997-02-07 | 2003-12-10 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods thereof |
| US6034062A (en) * | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
| US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| IT1296689B1 (it) | 1997-11-06 | 1999-07-14 | Fidia Advanced Biopolymers Srl | Derivati esterei dell'acido ialuronico aventi proprieta viscoelastiche e loro uso in campo biomedico-sanitario |
| US6630457B1 (en) * | 1998-09-18 | 2003-10-07 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
| IT1302534B1 (it) * | 1998-12-21 | 2000-09-05 | Fidia Advanced Biopolymers Srl | Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per |
| JP4211108B2 (ja) * | 1999-01-13 | 2009-01-21 | 生化学工業株式会社 | 高粘弾性物質の注入器具 |
| ES2225241T3 (es) * | 1999-10-15 | 2005-03-16 | Genetics Institute, Llc | Formulaciones de acido hialuronico para suministrar proteinas osteogenicas. |
-
2003
- 2003-05-12 BR BR0310087-1A patent/BR0310087A/pt not_active IP Right Cessation
- 2003-05-12 CN CN038160188A patent/CN1665525A/zh active Pending
- 2003-05-12 EP EP03726735A patent/EP1519744A4/en not_active Withdrawn
- 2003-05-12 CA CA002486113A patent/CA2486113A1/en not_active Abandoned
- 2003-05-12 TW TW095124486A patent/TW200638946A/zh unknown
- 2003-05-12 JP JP2004508234A patent/JP4879482B2/ja not_active Expired - Fee Related
- 2003-05-12 US US10/525,441 patent/US20050287135A1/en not_active Abandoned
- 2003-05-12 AU AU2003228958A patent/AU2003228958C1/en not_active Ceased
- 2003-05-12 MX MXPA04011337A patent/MXPA04011337A/es active IP Right Grant
- 2003-05-12 WO PCT/US2003/014609 patent/WO2003099992A2/en active Application Filing
- 2003-05-12 NZ NZ536478A patent/NZ536478A/en not_active IP Right Cessation
- 2003-05-12 EA EA200401502A patent/EA008354B1/ru not_active IP Right Cessation
- 2003-05-12 TW TW092112842A patent/TWI282283B/zh active
- 2003-05-16 AR ARP030101720A patent/AR039548A1/es unknown
-
2004
- 2004-11-07 IL IL16507704A patent/IL165077A0/xx unknown
- 2004-11-10 ZA ZA200409096A patent/ZA200409096B/en unknown
- 2004-12-07 CO CO04122903A patent/CO5631458A2/es not_active Application Discontinuation
- 2004-12-16 NO NO20045507A patent/NO20045507L/no not_active Application Discontinuation
-
2009
- 2009-03-31 US US12/414,715 patent/US7875590B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWI282283B (en) | 2007-06-11 |
| TW200307559A (en) | 2003-12-16 |
| CN1665525A (zh) | 2005-09-07 |
| US20090181058A1 (en) | 2009-07-16 |
| EP1519744A4 (en) | 2007-10-03 |
| JP2005532335A (ja) | 2005-10-27 |
| CO5631458A2 (es) | 2006-04-28 |
| AU2003228958A1 (en) | 2003-12-12 |
| EP1519744A2 (en) | 2005-04-06 |
| CA2486113A1 (en) | 2003-12-04 |
| WO2003099992A2 (en) | 2003-12-04 |
| MXPA04011337A (es) | 2005-07-01 |
| AR039548A1 (es) | 2005-02-23 |
| TW200638946A (en) | 2006-11-16 |
| NZ536478A (en) | 2008-02-29 |
| AU2003228958A2 (en) | 2003-12-12 |
| AU2003228958B2 (en) | 2008-05-01 |
| WO2003099992A3 (en) | 2004-05-27 |
| IL165077A0 (en) | 2005-12-18 |
| EA008354B1 (ru) | 2007-04-27 |
| US20050287135A1 (en) | 2005-12-29 |
| NO20045507L (no) | 2004-12-16 |
| US7875590B2 (en) | 2011-01-25 |
| EA200401502A1 (ru) | 2005-08-25 |
| BR0310087A (pt) | 2005-08-16 |
| JP4879482B2 (ja) | 2012-02-22 |
| AU2003228958C1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7875590B2 (en) | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins | |
| US7608580B2 (en) | Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins | |
| US8507008B2 (en) | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins | |
| KR20050019075A (ko) | 골형성 단백질의 전달을 위한 주사가능한 고체 히알루론산담체 | |
| EP1481695A1 (en) | Formulations of hyaluronic acid for delivery of osteogenic proteins | |
| MXPA06002384A (en) | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |